Obesity is more than a cosmetic concern. It’s a chronic disease that can be treated with drugs like semaglutide (Wegovy) and ...

Novo Nordisk’s obesity drug CagriSema’s test results showed an average weight loss of over 20%, but its stock slid in ...

Here are some clinical trials that could send Big Pharma shares soaring, or crashing, in 2025. Eli Lilly. The world’s biggest ...

Novo Nordisk retains a strong market position in a high-growth industry, with P/E multiples poised to expand. See why NVO ...

Alabama now provides partial GLP-1 coverage for obesity: Among the obesity-indicated GLP-1s, Medicaid in Alabama covers just ...

The weight-loss market began feeling some growing pains as the year ended, creating more wariness for the upcoming year. For 2025, competition and supply constraints are areas to watch.

A new technology is disrupting the economy. Even experts don’t entirely understand how it works, its full range of uses and ...

The holidays can be a difficult time for those with a history of eating disorders, and having someone comment on their body – ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

In a new study, an experimental obesity drug from Novo Nordisk called CagriSema allowed people to lose more than 20% of their ...

In a new study, an experimental obesity drug from Novo Nordisk called CagriSema allowed people to lose more than 20 percent of their body weight, on average, a result that caused the Danish company’s ...

After about 10 months of being on Ozempic and working my way up to a 1-mg dose, I lost 40 pounds effortlessly. Sugar cravings disappeared as if by magic. I then noticed myself drifting backward and ...